JP2018027929A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018027929A5 JP2018027929A5 JP2017026907A JP2017026907A JP2018027929A5 JP 2018027929 A5 JP2018027929 A5 JP 2018027929A5 JP 2017026907 A JP2017026907 A JP 2017026907A JP 2017026907 A JP2017026907 A JP 2017026907A JP 2018027929 A5 JP2018027929 A5 JP 2018027929A5
- Authority
- JP
- Japan
- Prior art keywords
- strontium
- formulation
- formulation according
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 238000009472 formulation Methods 0.000 claims 23
- 229920000642 polymer Polymers 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 5
- 229960004308 acetylcysteine Drugs 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 229910052712 strontium Inorganic materials 0.000 claims 5
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000003251 Pruritus Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- -1 cationic strontium salts Chemical class 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 claims 2
- IATRAKWUXMZMIY-UHFFFAOYSA-N strontium oxide Chemical compound [O-2].[Sr+2] IATRAKWUXMZMIY-UHFFFAOYSA-N 0.000 claims 2
- UBXAKNTVXQMEAG-UHFFFAOYSA-L strontium sulfate Chemical compound [Sr+2].[O-]S([O-])(=O)=O UBXAKNTVXQMEAG-UHFFFAOYSA-L 0.000 claims 2
- ZLCOWUKVVFVVKA-WDSKDSINSA-N (2r)-3-[[(2r)-2-acetamido-2-carboxyethyl]disulfanyl]-2-aminopropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSSC[C@H](N)C(O)=O ZLCOWUKVVFVVKA-WDSKDSINSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- ZWZDILQREOBSST-UHFFFAOYSA-N [Sr].S Chemical compound [Sr].S ZWZDILQREOBSST-UHFFFAOYSA-N 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 229920006318 anionic polymer Polymers 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- QCNCAQHKMMAWSP-UHFFFAOYSA-N butanedioic acid;strontium Chemical compound [Sr].OC(=O)CCC(O)=O QCNCAQHKMMAWSP-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- HSPYGHDTVQJUDE-LURJTMIESA-N dacisteine Chemical compound CC(=O)N[C@H](C(O)=O)CSC(C)=O HSPYGHDTVQJUDE-LURJTMIESA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229960000633 dextran sulfate Drugs 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- MLCQLNYCRIEWMX-ZZMNMWMASA-L strontium (2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-olate Chemical compound [Sr+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] MLCQLNYCRIEWMX-ZZMNMWMASA-L 0.000 claims 1
- 229910000018 strontium carbonate Inorganic materials 0.000 claims 1
- 229940013553 strontium chloride Drugs 0.000 claims 1
- 229910001631 strontium chloride Inorganic materials 0.000 claims 1
- 229940047908 strontium chloride hexahydrate Drugs 0.000 claims 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims 1
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 claims 1
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 claims 1
- 229910001866 strontium hydroxide Inorganic materials 0.000 claims 1
- 159000000008 strontium salts Chemical class 0.000 claims 1
- XUBXWWLLZIPPHW-DFWYDOINSA-L strontium;(2s)-2-aminopentanedioate Chemical compound [Sr+2].[O-]C(=O)[C@@H](N)CCC([O-])=O XUBXWWLLZIPPHW-DFWYDOINSA-L 0.000 claims 1
- CCUZKVDGQHXAFK-UHFFFAOYSA-L strontium;2-hydroxypropanoate Chemical compound [Sr+2].CC(O)C([O-])=O.CC(O)C([O-])=O CCUZKVDGQHXAFK-UHFFFAOYSA-L 0.000 claims 1
- GBIVDQYBCRNZBY-UHFFFAOYSA-L strontium;2-oxopentanedioate Chemical compound [Sr+2].[O-]C(=O)CCC(=O)C([O-])=O GBIVDQYBCRNZBY-UHFFFAOYSA-L 0.000 claims 1
- YXAMJFINXWQMCB-UHFFFAOYSA-L strontium;2-oxopropanoate Chemical compound [Sr+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O YXAMJFINXWQMCB-UHFFFAOYSA-L 0.000 claims 1
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 claims 1
- LVZZABGEQTZXHP-UHFFFAOYSA-L strontium;propanedioate Chemical compound [Sr+2].[O-]C(=O)CC([O-])=O LVZZABGEQTZXHP-UHFFFAOYSA-L 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229940022036 threonate Drugs 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- QGAPCDHPGCYAKM-UHFFFAOYSA-H tristrontium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QGAPCDHPGCYAKM-UHFFFAOYSA-H 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087003A JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208249P | 2015-08-21 | 2015-08-21 | |
| US15/239,171 | 2016-08-17 | ||
| US15/239,171 US20170049807A1 (en) | 2015-08-21 | 2016-08-17 | Strontium based compositions and formulations for pain, pruritus, and inflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087003A Division JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018027929A JP2018027929A (ja) | 2018-02-22 |
| JP2018027929A5 true JP2018027929A5 (https=) | 2020-03-05 |
| JP7103752B2 JP7103752B2 (ja) | 2022-07-20 |
Family
ID=58157450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017026907A Active JP7103752B2 (ja) | 2015-08-21 | 2017-02-16 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
| JP2021087003A Active JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087003A Active JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170049807A1 (https=) |
| JP (2) | JP7103752B2 (https=) |
| AU (2) | AU2017201085B2 (https=) |
| ES (1) | ES2925861T3 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3172684B2 (ja) | 1996-12-03 | 2001-06-04 | ワイケイケイアーキテクチュラルプロダクツ株式会社 | 断熱サッシ |
| KR101729096B1 (ko) | 2012-03-21 | 2017-04-21 | 코스메덤 바이오사이언스, 인코퍼레이티드 | 통증, 가려움증 및 염증을 치료하기 위한 국소 투여된 스트론튬-함유 복합체 |
| US11235002B2 (en) | 2015-08-21 | 2022-02-01 | Galleon Labs Llc | Strontium based compositions and formulations for pain, pruritus, and inflammation |
| WO2019210035A1 (en) * | 2018-04-25 | 2019-10-31 | Horizon Orphan Llc | Methods of treating excitotoxicity disorders |
| WO2022173813A1 (en) * | 2021-02-09 | 2022-08-18 | The Regents Of The University Of California | Improved bhb-citrate formulations for promoting health |
| CN113041487B (zh) * | 2021-04-23 | 2025-01-28 | 佳木斯大学 | 一种90锶敷贴器治疗装置 |
| CN114452297B (zh) * | 2021-12-30 | 2024-03-12 | 河南大新药业有限公司 | 一种治疗皮炎的药物制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051609A (en) * | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
| AU618517B2 (en) * | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
| US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| WO2001019361A2 (en) * | 1999-09-14 | 2001-03-22 | Tepha, Inc. | Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| NO20014746D0 (no) * | 2001-09-28 | 2001-09-28 | Clas M Kjoelberg | Smertelindrende middel |
| KR101729096B1 (ko) * | 2012-03-21 | 2017-04-21 | 코스메덤 바이오사이언스, 인코퍼레이티드 | 통증, 가려움증 및 염증을 치료하기 위한 국소 투여된 스트론튬-함유 복합체 |
-
2016
- 2016-08-17 US US15/239,171 patent/US20170049807A1/en not_active Abandoned
-
2017
- 2017-02-16 JP JP2017026907A patent/JP7103752B2/ja active Active
- 2017-02-16 ES ES17156555T patent/ES2925861T3/es active Active
- 2017-02-17 AU AU2017201085A patent/AU2017201085B2/en active Active
-
2021
- 2021-05-24 JP JP2021087003A patent/JP7322094B2/ja active Active
-
2023
- 2023-08-31 AU AU2023222925A patent/AU2023222925B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018027929A5 (https=) | ||
| JP2015510943A5 (https=) | ||
| JP6458124B2 (ja) | アポモルヒネと有機酸とを含む組成物およびその使用 | |
| HRP20200366T1 (hr) | Kontinuirana primjena l-dopa, inhibitora dopa-dekarboksilaze, inhibitora katekol-o-metil-transferaze i njihovih pripravaka | |
| JPS63502186A (ja) | 粘膜上のゲルの付着性を改善する方法 | |
| ES2944311T3 (es) | Formulaciones de fenilacetato de L-ornitina | |
| RU2014142259A (ru) | Применяемые местно стронцийсодержащие комплексы для лечения боли, зуда и воспаления | |
| JP5627854B2 (ja) | 胃の逆流抵抗性投薬形態 | |
| JP2012255018A (ja) | 感覚器官的に許容されるイブプロフェン経口投与用製剤、該製剤の製法並びに使用法 | |
| JP2022179727A (ja) | リナクロチドの改変または標的放出製剤 | |
| JP2015518038A5 (https=) | ||
| Sandri et al. | Mucoadhesive polymers as enabling excipients for oral mucosal drug delivery | |
| RU2016121401A (ru) | Устойчивые при хранении лиофилизованные составы трипептидов | |
| US20180064669A1 (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| JP2020196677A (ja) | 錠剤の製造方法 | |
| CN106667944A (zh) | 含有前列腺素类药物的缓释制剂 | |
| JP2010540448A5 (https=) | ||
| AU2020204558A1 (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| JP7105057B2 (ja) | 口腔用組成物 | |
| JP5572110B2 (ja) | 粘膜の疾患および障害の予防および処置のための液体製剤 | |
| US11291673B2 (en) | Topical doxycycline hydrogel with improved long-term stability | |
| JP7291847B2 (ja) | 生体適合性材料 | |
| JP6697402B2 (ja) | 機能性物質を高含有する錠剤及びその製造方法 | |
| RU2015112586A (ru) | Фармацевтические композиции, содержащие флурбипрофен | |
| CN107753446A (zh) | 一种雷沙吉兰片剂及其制备方法 |